Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Anemia, Refractory 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 11Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3trametinib 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1pembrolizumab 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Vorinostat × 90 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡